National Institute of Allergy and Infectious Diseases

October 20, 2023

Bryan Shepherd’s research to validate EHR data receives MERIT Award from the NIH

Vanderbilt’s Bryan Shepherd, PhDhas received a MERIT Award, or Method to Extend Research in Time Award, from the National Institute of Allergy and Infectious Diseases.

By Paul Govern
A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.
July 21, 2022

Study explores role RSV plays in later asthma development

A Vanderbilt clinical project will follow 1,950 Middle Tennessee children to determine how genes and the environment interact with RSV infection during the first year of life and contribute to asthma development

By Leah Mann
February 24, 2022

Study to explore neurologic impact of flu treatment

A Vanderbilt study will explore the neurologic and psychiatric complications of flu and evaluate adverse effects of the antiviral treatment oseltamivir, also known by the brand name Tamiflu.

By Jessica Pasley
May 12, 2021

Fauci shares lessons learned during pandemic response with Vanderbilt MPH students

Anthony Fauci, MD, chief medical adviser to President Joe Biden’s administration and director of the National Institute of Allergy and Infectious Diseases (NIAID), recently met virtually with students of Vanderbilt University School of Medicine’s Master of Public Health (MPH) program to answer questions about lessons learned during the pandemic and to share career advice.

By Jill Clendening
February 11, 2021

Clinical Trials Unit lands major grant renewal

Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have received renewal of a major federal grant to continue their collaboration to test and develop new treatments and vaccines against HIV/AIDS — and now COVID-19.

By Bill Snyder
December 17, 2020

Clinic uses new weapon to treat high-risk COVID patients

Vanderbilt University Medical Center has a new weapon in the fight against COVID-19 — an investigational antibody treatment approved last month for emergency use in COVID-19 outpatients at high risk of developing severe disease or requiring hospital care.

By Bill Snyder
June 4, 2020

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
By Bill Snyder
June 28, 2011

Inflammation relief: what’s the delay?

New research offers hope for patients needing the anti-inflammatory benefits of glucocorticoids without the adverse side effects associated with them.
By VUMC News and Communications